| Website | thirdrockventures... |
| Phone | (617) 585-2000 |
| Employees | |
| Founded | 2007 |
| Total | $942M |
| Fund II, 9/10 | $426M |
| Fund III, 3/13 | $516M |
Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace.
| Company | Date | Round | Size | Participants |
| TARIS Biomedical | 4/13 | Private Equity | $12.5M | 4 |
| DC Devices | 3/13 | Series A | $9M | 3 |
| Kala Pharmaceuticals | 2/13 | Series A | $11.5M | 4 |
| Jounce Therapeutics | 2/13 | Series A | $47M | 1 |
| Zafgen | 12/12 | Series D | $21M | 3 |
| Rhythm Pharmaceuticals | 11/12 | Series B | $8M | 5 |
| Cibiem | 10/12 | Series A | $10M | 2 |
| MyoKardia | 9/12 | Series A | $38M | 1 |
| Foundation Medicine | 9/12 | Series B | $42.5M | 7 |
| bluebird bio | 7/12 | Series D | $60M | 7 |
| Global Blood Therapeutics | 6/12 | Series A | $40.7M | 1 |
| Rhythm Pharmaceuticals | 6/12 | Series B | $25M | 4 |
| Igenica | 6/12 | Series C | $33M | 4 |
| Eleven Biotherapeutics | 5/12 | Series A | $20M | 3 |
| Alcresta | 4/12 | Series A | $10M | 3 |
| Kala Pharmaceuticals | 3/12 | Venture Round | $6.2M | 4 |
| Warp Drive Bio | 1/12 | Venture Round | $125M | 3 |
| Ember Therapeutics | 12/11 | Series A | $34M | 1 |
| Agios Pharmaceuticals | 11/11 | Series C | $78M | 4 |
| Allena Pharmaceuticals | 11/11 | Series A | $15M | 3 |
| Topica Pharmaceuticals | 10/11 | Series B | $27M | 3 |
| SAGE Therapeutics | 10/11 | Series A | $35M | 1 |
| Foundation Medicine | 10/11 | Series A | $33.5M | 3 |
| Zafgen | 7/11 | Series C | $33M | 2 |
| Lotus Tissue Repair | 6/11 | Series A | $26M | 1 |
| Constellation Pharmaceuticals | 6/11 | Series B | $15M | 5 |
| Seventh Sense Biosystems | 5/11 | Series A | $4.5M | 3 |
| bluebird bio | 4/11 | Venture Round | $30M | 5 |
| TARIS Biomedical | 4/11 | Series B | $18.3M | 4 |
| Blueprint Medicines | 4/11 | Series A | $40M | 2 |
| PanOptica | 1/11 | Series A | $30M | 2 |
| NinePoint Medical | 10/10 | Series A | $33M | 2 |
| CytomX Therapeutics | 9/10 | Series B | $30M | 2 |
| Constellation Pharmaceuticals | 6/10 | Series B | $4.8M | 5 |
| Ablexis | 6/10 | Series A | $12M | 2 |
| Zafgen | 3/10 | Series B | $28M | 3 |
| bluebird bio | 3/10 | Series B | $35M | 5 |
| Eleven Biotherapeutics | 3/10 | Series A | $35M | 2 |
| Afferent Pharmaceuticals | 12/09 | Series A | $23M | 4 |
| Constellation Pharmaceuticals | 8/09 | Series B | $17.2M | 4 |
| Alnara Pharmaceuticals | 10/08 | Series A | $20M | 3 |